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ABSTRACT
Introduction: Management of a patient’s diabetes is
entirely dependent upon the type of diabetes they are
deemed to have. Patients with Type 1 diabetes are
insulin deficient so require multiple daily insulin
injections, whereas patients with Type 2 diabetes still
have some endogenous insulin production so insulin
treatment is only required when diet and tablets do not
establish good glycaemic control. Despite the
importance of a correct diagnosis, classification of
diabetes is based on aetiology and relies on clinical
judgement. There are no clinical guidelines on how to
determine whether a patient has Type 1 or Type 2
diabetes. We aim to systematically review the literature
to derive evidence-based clinical criteria for the
classification of the major subtypes of diabetes.
Methods and analysis: We will perform a systematic
review of diagnostic accuracy studies to establish
clinical criteria that predict the subsequent development
of absolute insulin deficiency seen in Type 1 diabetes.
Insulin deficiency will be determined by reference
standard C-peptide concentrations. Synthesis of criteria
identified will be undertaken using hierarchical
summary receiver operating characteristic curves.
Ethics and dissemination: As this is a systematic
review, there will be no ethical issues. We will
disseminate results by writing up the final systematic
review and synthesis for publication in a peer-reviewed
journal and will present at national and international
diabetes-related meetings.
INTRODUCTION
Correct classiﬁcation of a patient’s diabetes is
crucial to ensure they are provided with the
most appropriate treatment, management
and education. There are two main subtypes
of diabetes: Type 1 diabetes (∼15%) and
Type 2 diabetes (∼83%),1 in addition to
other rare genetic or secondary subtypes.
ARTICLE SUMMARY
Article focus
▪ Current guidelines for classifying Type 1 and
Type 2 diabetes according to WHO, ADA and
NICE, are based on aetiology rather than clinical
criteria.
▪ Differences in the treatment and management of
Type 1 and Type 2 diabetes are all based on
whether a patient is producing their own insulin
(Type 1) or not (Type 2).
▪ We aim to systematically review the literature to
identify clinical criteria that can be used to
predict absolute insulin deficiency (as seen in
Type 1 diabetes) that can be used in the classifi-
cation of diabetes.
Key messages
▪ Misclassification of diabetes has been high-
lighted as a problem. There are currently no
evidence-based criteria that can be used to clas-
sify Type 1 and Type 2 diabetes.
▪ We aim to systematically review the literature to
identify clinical criteria that can be used to
predict absolute insulin deficiency (as seen in
Type 1 diabetes).
▪ We aim to synthesise the results to produce cri-
teria that can be used in the classification of
diabetes.
Strengths and limitations of this study
▪ Our review will be systematic and exhaustive.
Our search strategy encompasses a large
number of electronic databases and websites,
including those to examine grey literature, and
we are not restricting our search to English lan-
guage only.
▪ The only clinical criteria currently proposed for
classification (from the Royal College of GPs/
NHS Diabetes) are based on expert-opinion—our
study will provide evidence-based criteria.
▪ A validation study will be necessary to determine
the utility of the criteria identified in practice.
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Differences in the NICE (National Institute of Clinical
Excellnce) guidelines for Type 12 and Type 23 diabetes
are marked and include the treatment used (patients
with Type 1 diabetes will start on multiple insulin injec-
tions while those with Type 2 diabetes will only go to
insulin if diet and tablets do not control blood glucose),
the dietary advice given, and the monitoring required by
patients and their healthcare team. These major differ-
ences are vital to ensure optimal glycaemic control for
the patient and hence reduce their long-term risk of
complications. The clear differences in clinical care in
these patients are entirely based on assumptions of dif-
ferences in endogenous insulin secretion.
Despite clinical guidance being speciﬁc for Type 1
and Type 2 diabetes, there are no published, evidence-
based, clinical criteria that can be used to deﬁne a
patient’s type of diabetes. Guidance on the classiﬁcation
of the two types of diabetes from major health organisa-
tions is limited, and primarily focuses on aetiology. The
WHO deﬁnes Type 1 diabetes as ‘β-cell destruction,
usually leading to absolute insulin deﬁciency’ mainly
occurring as the result of an autoimmune process.4 5
Type 2 diabetes is described by WHO as ‘ranging from
predominantly insulin resistance with relative insulin
deﬁciency to predominantly an insulin secretory defect
with insulin resistance’.4 5 Essentially, the key difference
between the two types of diabetes is whether the patient
continues to produce their own insulin or not. Insulin
deﬁciency/production can be assessed by measurement
of C-peptide concentrations in either blood or urine,6 7
but this measurement is rarely carried out in practice.
Classiﬁcation is based on clinical judgement.
Classiﬁcation used to be relatively easy with Type 1
diabetes being traditionally thought of as a young-onset
disease that presents acutely and Type 2 diabetes being
associated with obesity and older age. However, these
indications are not always helpful. Patients with Type 2
diabetes can present with ketoacidosis and the onset of
autoimmune diabetes can be slower in older patients.
With the prevalence of obesity increasing in the popula-
tion as a whole, Type 2 diabetes is being seen in younger
patients and Type 1 patients can also be obese, so the
distinction between the two types is becoming blurred.
Discriminating Type 1 from Type 2 diabetes, particularly
in young-onset/middle-aged patients, has become more
challenging.8 Recent work has shown misclassiﬁcation of
diabetes can occur in up to 13–16% of cases9 10 so the
current practice based on aetiological guidelines and
clinical opinion is clearly insufﬁcient. A recent report by
the working group between NHS Diabetes and The
Royal College of General Practitioners has highlighted
this problem.10 Pragmatic guidelines on diabetes classiﬁ-
cation have been developed by this group, but are taken
from consensus expert clinical opinion rather than
being evidence based.10
Clearer, evidence-based guidelines on the classiﬁcation
of diabetes are needed to ensure patients are appropri-
ately managed and help reduce the errors in
misdiagnosis. As measures of endogenous insulin secre-
tion are rarely carried out in practice, the identiﬁcation
of clinical criteria that could be used as a surrogate to
help discriminate the two types of diabetes would be
invaluable, and could help form clearer guidelines for
clinicians.
We aim to derive evidence-based clinical criteria for
the classiﬁcation of the major subtypes of diabetes.
These are needed to inform local and national guide-
lines so healthcare practitioners can select the appropri-
ate treatment regimes for their patients. The main
objective will be to systematically review and synthesise
the medical literature to establish clinical criteria that
predict the subsequent development of absolute insulin
deﬁciency (measured by C peptide) seen in Type 1
diabetes.
METHODS AND ANALYSIS
Overview
A systematic review will be undertaken to identify, critique
and synthesise the evidence on clinical criteria that
predict absolute insulin deﬁciency that can be used in
the classiﬁcation of Type 1 diabetes. This can be consid-
ered a systematic review of diagnostic test accuracy, with
insulin deﬁciency representing the outcome and clinical
characteristics representing the predictors. The proposed
systematic review will be undertaken following the princi-
ples of systematic reviews as set out in NHS Centre for
Reviews and Dissemination guidelines.11 The protocol
has been registered with PROSPERO (http://www.crd.
york.ac.uk/prospero/, reference CRD42012001736). The
study designs that we will identify as relevant to this sys-
tematic review will be diagnostic studies where clinical
features, such as age at diagnosis and body mass index
(BMI), are compared against insulin deﬁciency as
deﬁned by reference standard C-peptide concentrations.
Population
Patients diagnosed with diabetes with evidence of insulin
deﬁciency, as determined by negative C-peptide results
(‘Type 1 diabetes’). Type 2 diabetes will be the exclusion
of Type 1 and other subtypes where the aetiology is
known (eg, secondary diabetes or monogenic diabetes).
The focus of the literature search will be on patients
with the more common forms of diabetes (ie, known
rare genetic, syndromic or secondary forms of diabetes
will be excluded). All ages and racial groups will be
considered.
Reference standard
For ‘Type 1 diabetes’, reference standard will be meas-
urement of C peptide to determine insulin deﬁciency.
All measurements will be considered including different
types of sample (urine or blood), different types of
stimulus (fasting, random, glucose-stimulated, mixed
meal-stimulated, postglucagon-stimulated), and timing
after stimulation (peak or area-under-curve of numerous
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measurements, 90 min, 2 h). The deﬁnition of insulin
deﬁciency used will be recorded and evaluated.
Comparator/predictor
Preliminary scoping has indicated that the major predic-
tors will be age at diagnosis and BMI, so the primary
focus will be on assessing their diagnostic accuracy and
the optimal thresholds of these for discriminating the
two types of diabetes. Any clinical features that can be
measured and replicated will be considered. Some cri-
teria will be subject to clinician judgement (eg, time to
insulin treatment, which is confounded by the clinician
considering their patient has Type 1 diabetes). A distinc-
tion will be made between those that can be used for
classiﬁcation at diagnosis and those that can be used
after diagnosis (eg, time to insulin treatment cannot be
used at diagnosis).
Outcomes
(i) The clinical features assessed to predict C-peptide
levels; (ii) the sensitivity and speciﬁcity of clinical fea-
tures as measured against insulin deﬁciency as deter-
mined by C peptide.
Study design
Diagnostic accuracy studies.
Search strategy
Our search approach will be systematic and exhaustive.
We propose searching for relevant literature in a variety
of ways so as to ensure sensitivity and depth of retrieval.
We intend to search not only for peer-reviewed publica-
tions but also grey literature. Our search strategy will
include
1. Electronic databases (see online supplementary
material for details of the databases that will be used
in the search strategy)
2. Websites—we propose searching websites as tools for
gathering grey—or difﬁcult to locate—literature (see
online supplementary material). Given the clinical
nature of our topic, it is unlikely these searches will
yield much information, so the list is somewhat
shorter than for a public health topic.
3. Pearl growing, Snowballing and Hand-searching—in
addition to searching electronic databases, we
propose citation chasing and contacting the authors
of included studies. These approaches have been
shown to yield additional information.12 13 Forward
citation chasing will be conducted in Web of Science
(ISI), and bibliographies of included studies will be
pursued by the review team to further enhance our
ability to capture all relevant literature. We will hand-
search the core journals identiﬁed by the number of
includes in our search, most likely to be Diabetes
Care, Diabetologia and Diabetic Medicine as the key
clinical diabetes journals.
Search limits
Searches will be limited to the date range 1979–present,
which reﬂects the original classiﬁcation scheme pro-
posed by the National Diabetes Data Group.14 The
searches will also be limited to human only populations.
We will not be restricting the search by language.15
Search recording
The exported ﬁles from the literature searching will be
uploaded and de-duplicated in Endnote X4 (Thomson
Reuters) and then imported into Microsoft Access for
reviewing purposes. Where an export is not possible, for
example, from a resource without RIS functionality, the
data will be exported to a word ﬁle and manually
entered into Endnote and Access. All ﬁles will be copied
and saved for record. The searches will be recorded
using PRISMA guidelines.16 An example of this search
recoding can be seen in online supplementary material.
Update searches
Towards the end of the review time line, we will repeat
the search process to bring our review up to date.
Study selection
There will be two stages to the identiﬁcation of relevant
studies to be included in the systematic review. First, the
titles and abstracts of all references identiﬁed by the
above search strategy will all be double-screened by two
reviewers. Any disagreements on inclusion of studies
between the two reviewers will be resolved by discussion,
or the inclusion of a third reviewer if necessary. Second,
the full text of all references identiﬁed as included at
the ﬁrst stage will be obtained and then assessed by both
reviewers. The references of all relevant studies will be
searched for any further relevant studies.
Data extraction
A standard data extraction form will be developed and
applied to all included studies. This data extraction form
will be piloted at the beginning of the research to
ensure it is sufﬁcient and captures all relevant informa-
tion. The information extracted from each study will
include: setting (eg, country, year), general patient
demographics (eg, age range, gender, racial group, type
of diabetes), measurement of insulin deﬁciency (eg, test
threshold, sample type), results (eg, predictors of C
peptide, magnitude of effect, statistical signiﬁcance, sen-
sitivity and speciﬁcity of predictor) and conclusions.
Study quality assessment
The QUADAS-2 (Quality Assessment of Diagnostic
Accuracy Studies) tool17 will be used to assess the quality
of the diagnostic accuracy studies included in the system-
atic review. This tool will help identify potential biases in
the primary studies so that the conclusions of the system-
atic review appropriately reﬂect the possible impact of
such biases. Particular attention will be paid to the refer-
ence standard, where details of the sample type, sample
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collection, stimulus used, storage, assay and cut-off used
will be recorded and assessed. Timing of measurements
in relation to diagnosis will also be recorded.
Data synthesis and exploration of bias
Data analysis will comprise four steps. The ﬁrst will be
the initial visualisation of the data by plotting the sensi-
tivity and speciﬁcity from all the included studies on the
ROC (receiver operating characteristic) space. This will
allow some assessment of the heterogeneity of the esti-
mates across the studies.
Second, we will use the Hierarchical Summary ROC
model18 19 to determine the overall diagnostic value and
sensitivity and speciﬁcity of individual diagnostic charac-
teristics at different thresholds.20 It is envisaged that age
at diagnosis and BMI will be the two main predictors for
absolute insulin deﬁciency. Univariate analysis of the
diagnostic value of these predictors (and any other
clinical features identiﬁed) will initially be conducted,
and, in cases where papers have reported two criteria
together linked ROC plots20 can be used to display how
the variables perform in combination. Where such ana-
lysis cannot be conducted, combinations will be consid-
ered on a rational basis. The reference standard is likely
to differ across the studies included in the systematic
review; therefore, subgroup analysis may need to be
carried out to explore the impact of the potential bias in
this. Hierarchical summary ROC models also incorpor-
ate random study effects enabling heterogeneity
between studies to be accounted for, but not explained.
The third step will be to investigate possible sources of
heterogeneity by the addition of covariates to the hier-
archical summary ROC models. As different criteria may
apply to different groups, these covariates will include
age (adults vs children), race and gender. However, such
analyses are limited by the number of studies included
in the systematic review and should be considered
exploratory as they are based on the study level covari-
ates.21 It will be important to separate out the criteria
which can be used at diagnosis and the criteria which
can be used after diagnosis.
Finally, we will investigate evidence on the existence of
reporting or publication bias within the systematic
review. Investigations of possible reporting or publication
bias in any systematic review are impacted by there being
a small number of included studies and between-study
heterogeneity. Therefore, exploratory analysis using
funnel plots and, if appropriate, a related test for funnel
plot asymmetry22 will be undertaken.
Initial scoping
The search syntax we have tested in our preliminary
scoping searches has been included in online supple-
mentary material. Applying this syntax to the two
primary databases, Medline and Embase, yields 5804
and 8566 results, respectively. Given that these two
searches will include considerable duplication (due to
the crossover between these two databases) and that
further studies will be identiﬁed from further databases,
we are estimating we will end up with 10 000 results for
screening. Approximately 10% of all search results in
our Medline scope were non-English language, however,
titles and abstracts are often available in English. From
initial scoping we are estimating we will identify 200
abstracts from which we will need to obtain full text, of
which we expect that, at the most, two will be of
non-English language and will require translation. From
the ﬁnal review of these articles, we anticipate 20 will be
suitable for the ﬁnal synthesis.
Ethics and dissemination
As this is a systematic review there will be no ethical
issues. We will disseminate results by writing up the ﬁnal
systematic review and synthesis for publication in a peer-
reviewed journal (reported using preferred reporting
items for systematic reviews and meta-analyses (PRISMA)
guidelines) and will present at the national and inter-
national diabetes-related meetings.
DISCUSSION
A systematic review of the literature on predictors of
insulin deﬁciency is an important ﬁrst step in determin-
ing evidence-based guidelines that can be used for classi-
ﬁcation of diabetes. By examining the current evidence
base, we can synthesise information on existing predic-
tors to determine a useful set of clinical criteria. The
next step will be to validate these criteria against gold
standards of insulin deﬁciency in datasets of patients
with C peptide measured.
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